Harrow Launches FDA-Approved Iheezo at ASCRS

Harrow announced the launch of FDA-approved Ihezzo at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California. The Harrow commercial team will be available to discuss Iheezo and the entire Harrow portfolio of ophthalmic pharmaceutical products at ASCRS booth #2237.

Iheezo is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. Iheezo, which has been issued a J‑Code (J2403) and transitional pass-through reimbursement status by CMS, represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.

Iheezo Launch Events

• Richard L. Lindstrom, MD, will be making a presentation titled, Prospective, Randomized Comparison of Chloroprocaine 3% Gel and Tetracaine 0.5% Solution for Cataract Surgery Anesthesia. The presentation is scheduled during the Medications (Preoperative, Postoperative, Intraoperative) session on Sunday, May 7th, beginning at 3:40 p.m. PT in the SDCC, Upper Level, Room 5A.
• William Wiley, MD, will speak about his experience using Iheezo during a booth talk scheduled to begin at 1:30 p.m. PT at Harrow’s booth #2237 on Saturday, May 6th.
• Harrow will host the “Harrow Brings Nashville to San Diego” Iheezo Launch Event at the Hard Rock Hotel in downtown San Diego from 5:30-7:30 p.m. on Saturday, May 6th.
  To attend the event and learn more about Iheezo, please register by clicking here.